A Study to Evaluate the Effect of Ibrutinib on the Pharmacokinetics of Oral Contraceptives, CYP2B6, and CYP3A4 Substrates in Female Participants With B Cell Malignancy

Inclusion Criteria:

* Histologically or cytologically confirmed chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), or Waldenstrom's macroglobulinemia (WM)

  1. Participants with MCL must have relapsed or refractory disease after at least 1 prior line of systemic therapy
  2. Participants with MZL must have failed an anti-cluster of differentiation (CD)20 monoclonal antibody-based therapy
* Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1
* Adequate hematologic, hepatic, and renal functions
* Before the first dose of oral contraceptive (OC), a woman must be either:

  1. Not of childbearing potential: postmenopausal (greater than \[\>\]45 years of age with amenorrhea for at least 12 months and a serum follicle stimulating hormone level \>40 international unit per Liter \[IU/L\] or milli international unit per milli Liter \[mIU/mL\]); permanently sterilized
  2. Of childbearing potential and practicing a highly effective non-hormonal method of birth control
* Women of childbearing potential must have a negative serum (Beta-human chorionic gonadotropin \[Beta-hCG\]) or urine pregnancy test at screening

Exclusion Criteria:

* Major surgery planned within 2 weeks of the first dose of ibrutinib or during study participation up to Cycle 2 Day 1
* History of other malignancies, except:

  1. Malignancy treated with curative intent and with no known active disease present for greater than or equal to (\>=)3 years before the first dose of ibrutinib and felt to be at low risk for recurrence by treating physician
  2. Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease
  3. Adequately treated in-situ cancer without evidence of disease
* History of breast or endometrial cancer
* Prior treatment/exposure with ibrutinib or other Bruton's tyrosine kinase (BTK) inhibitor
* Requires ongoing anticoagulation treatment with warfarin or equivalent vitamin K antagonists (for example, phenprocoumon)
* Requires therapies that must be discontinued or substituted 7 days prior to Study Day 1, or must be temporally interrupted during the course of the study, including the following:

  1. Medications known to induce or inhibit drug metabolizing enzymes (CYP3A4 and CYP2B6)
  2. Medication which are not allowed to be used in combination with EE, LN, bupropion, or midazolam